CK Life Sciences
Corporate brand
UnclaimedCK Life Sciences is a Hong Kong-listed life sciences company focused on researching, commercializing, marketing, and selling biotechnology-related products and services.
Last updated August 25, 2026
Overview
CK Life Sciences International (Holdings) Inc., commonly known as CK Life Sciences, is a life sciences company associated with CK Hutchison Holdings. Established in 2000, the company was created to pursue the research, development, commercialization, marketing, and sale of biotechnology products and related applications. Its activities have covered agricultural products, health-related foods and supplements, and environmental remediation, reflecting a broad commercialization model rather than a focus on a single therapeutic category. The company became a public company in Hong Kong in 2002, when its shares were listed on the Growth Enterprise Market under the former stock code 8222. In 2008, the company transferred its listing to the Main Board of the Hong Kong Stock Exchange, where it trades under stock code 0775. Its corporate development has therefore combined life sciences activities with the capital-market infrastructure and international expansion associated with the wider CK group. CK Life Sciences has operated across Hong Kong, Mainland China, Australia, North America, and Europe. Its agricultural interests expanded through the acquisition of Australian salt producer Cheetham Salt in 2012. That transaction broadened the group's exposure to agricultural inputs and natural-resource-related activities alongside its biotechnology and health-product businesses. The company’s business scope is organized around applying scientific research to products that can be commercialized in consumer, agricultural, and environmental settings. Its typical activities include agricultural biotechnology and inputs, health foods and nutritional products, and technologies or services associated with environmental cleanup and remediation. Public descriptions of the company emphasize research and development as well as commercialization, marketing, and sales, rather than describing CK Life Sciences solely as a laboratory or investment vehicle. CK Life Sciences is chaired by Victor Li Tzar-kuoi, who is also associated with the leadership of the broader CK Hutchison group. In October 2024, the company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for US$100 million. The transaction represented a portfolio change within its life sciences operations and reduced its direct ownership of that Canadian pharmaceutical subsidiary. CK Life Sciences remains an active listed company with a diversified life sciences portfolio.
History
CK Life Sciences International (Holdings) Inc. was established in 2000 as a life sciences company associated with the CK group. Its stated activities include research and development, commercialization, marketing, and the sale of biotechnology products. Rather than concentrating exclusively on conventional pharmaceuticals, the company developed a diversified scope spanning agricultural applications, health-related products, and environmental remediation. The company entered Hong Kong’s public markets in 2002 through a listing on the Growth Enterprise Market. At that time, it traded under stock code 8222. The listing provided a public-company structure for a business whose strategy combined scientific development with commercialization and international expansion. In 2008, CK Life Sciences transferred from the Growth Enterprise Market to the Main Board of the Hong Kong Stock Exchange and adopted its current stock code, 0775. Its geographic footprint has included Hong Kong, Mainland China, Australia, North America, and Europe. Australia became particularly important to the company's agricultural expansion. In 2012, CK Life Sciences acquired Cheetham Salt, an Australian salt company, adding an agricultural and resource-related business to its wider life sciences portfolio. The acquisition demonstrated that the company's interpretation of life sciences included commercially scalable agricultural products and inputs in addition to laboratory-developed biotechnology. CK Life Sciences has also been associated with products and services in health foods and nutritional supplementation. These activities complement its agricultural and environmental interests and give the company exposure to consumer-facing applications of life sciences research. Environmental remediation represents another part of its stated business scope, extending the company's activities into technologies and services intended to address contaminated or degraded environments. The company’s corporate leadership is linked to the wider CK group. Victor Li Tzar-kuoi is identified as its chairman and is also a senior figure within CK Hutchison Holdings. CK Life Sciences is a subsidiary of CK Hutchison Holdings and operates as a separately listed life sciences company within that broader corporate structure. In October 2024, CK Life Sciences divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for US$100 million. The disposal marked a change in the composition of its pharmaceutical-related holdings and showed that the company continues to adjust its portfolio through transactions as well as through internal research, product development, and commercialization. CK Life Sciences remains active and listed on the Hong Kong Stock Exchange, with a business model spanning biotechnology products, agricultural activities, health products, and environmental applications.
- 2024
WEX Pharmaceuticals divestment
[1]In October, CK Life Sciences agreed to sell Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for US$100 million.
- 2012
Cheetham Salt acquisition
[1]CK Life Sciences acquired Australian salt company Cheetham Salt as part of its expansion into agriculture.
- 2008
Transfer to the Main Board
[1]CK Life Sciences transferred its Hong Kong listing from the Growth Enterprise Market to the Main Board, where it trades under stock code 0775.
- 2002
Hong Kong Growth Enterprise Market listing
[1]The company listed on the Hong Kong Stock Exchange's Growth Enterprise Market under former stock code 8222.
- 2000
Company established
[1]CK Life Sciences was established as a company focused on life sciences research, development, commercialization, marketing, and sales.
Products and positioning
A diversified life sciences platform that develops, commercializes, markets, and sells biotechnology-related products for agricultural, health, and environmental applications.
Agricultural biotechnology
Agricultural biotechnology products
This category covers biotechnology-related products and agricultural inputs developed or commercialized for use in farming and related agricultural activities. It reflects CK Life Sciences' effort to apply life sciences research beyond healthcare and into commercially scalable agricultural applications.
Consumer health
Health foods and nutritional supplements
CK Life Sciences has operated in health foods and nutritional supplements, placing life sciences research into consumer-facing products. Public reference material identifies this as a business area, but does not provide a sufficiently detailed product catalogue for individual brands or formulations.
Environmental biotechnology
Environmental remediation solutions
Environmental remediation is part of the company's stated life sciences scope. The category includes technologies or services intended to help address environmental contamination or degradation, although the available reference material does not identify specific commercial product names.
Agricultural and industrial salt
Cheetham Salt
Cheetham Salt is an Australian salt business acquired by CK Life Sciences in 2012 during the group's agricultural expansion. It represents an operating business and agricultural-sector holding within the broader CK Life Sciences portfolio rather than a biotechnology product in the narrow sense.
Pharmaceutical subsidiary
WEX Pharmaceuticals
WEX Pharmaceuticals was a Canadian subsidiary of CK Life Sciences. The company divested WEX Pharmaceuticals to Virios Therapeutics in October 2024 for US$100 million, so it should be treated as a former portfolio company rather than a current CK Life Sciences offering.
Brand decisions
2024
Sale of WEX PharmaceuticalsM&ABackground
WEX Pharmaceuticals was a Canadian subsidiary within CK Life Sciences' pharmaceutical-related portfolio.
Action taken
In October 2024, CK Life Sciences sold WEX Pharmaceuticals to Virios Therapeutics.
Aftermath
The transaction removed WEX Pharmaceuticals from CK Life Sciences' portfolio and represented a divestment of a Canadian pharmaceutical subsidiary.
Transaction value. US$100 million (October 2024)
2012
Acquisition of Cheetham SaltM&ABackground
CK Life Sciences sought to expand its activities in the agricultural sector and broaden its operating portfolio.
Action taken
The company acquired Australian salt producer Cheetham Salt.
Aftermath
The transaction increased the company's exposure to Australian agriculture and salt-related operations.
2008
Transfer of the Hong Kong listing to the Main BoardStrategyBackground
CK Life Sciences had initially been listed on the Hong Kong Stock Exchange's Growth Enterprise Market under stock code 8222.
Action taken
The company transferred its listing to the Main Board and subsequently traded under stock code 0775.
Aftermath
The move placed CK Life Sciences within the Hong Kong Stock Exchange Main Board structure.
Recent events
- 2024
CK Life Sciences divests WEX Pharmaceuticals to Virios Therapeutics[1]
M&A
CK Life Sciences sold its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics in October 2024 for US$100 million.
- 2012
CK Life Sciences acquires Australian salt company Cheetham Salt[1]
M&A
The company acquired Australian salt producer Cheetham Salt as part of an expansion of its agricultural activities.
- 2008
CK Life Sciences transfers listing from Hong Kong GEM to Main Board[1]
Other
CK Life Sciences moved its Hong Kong listing from the Growth Enterprise Market to the Main Board. Its former GEM stock code was 8222; its current Main Board code is 0775.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ck-life-sciences · Editorial policy · How profiles are compiled